The present invention relates generally to the field of medicine, and in particular, to methods for preparing nanovector-based drug delivery compositions. Disclosed are biomimetic proteolipid nanovesicles that possess remarkable properties for targeting compounds of interest to particular mammalian cells and tissue types. In particular embodiments, methods are disclosed for producing these vesicles that employ a microfluidics-based synthesis (including those employing the NanoAssemblr® platform), which allows for the high-throughput, reproducible, and scalable production of nanoparticles, without affecting their pharmaceutical and biological properties, are described. The versatility of a microfluidics-based approach makes it suitable for good manufacturing practice (GMP)-compliant manufacture of such biomimetic nanoparticles.
MICROFLUIDIC-FORMULATED LEUKOSOME COMPOSITIONS AND FABRICATION METHODS THEREFOR
TASCIOTTI E;
2017-01-01
Abstract
The present invention relates generally to the field of medicine, and in particular, to methods for preparing nanovector-based drug delivery compositions. Disclosed are biomimetic proteolipid nanovesicles that possess remarkable properties for targeting compounds of interest to particular mammalian cells and tissue types. In particular embodiments, methods are disclosed for producing these vesicles that employ a microfluidics-based synthesis (including those employing the NanoAssemblr® platform), which allows for the high-throughput, reproducible, and scalable production of nanoparticles, without affecting their pharmaceutical and biological properties, are described. The versatility of a microfluidics-based approach makes it suitable for good manufacturing practice (GMP)-compliant manufacture of such biomimetic nanoparticles.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
